Browse regulations

Amends the General Medical Services Table to specify services covered by health insurance, likely aiming to standardize coverage for medical procedures.

The regulation imposes unnecessary bureaucratic constraints on healthcare providers and patients, inflates insurance premiums through rigid coverage definitions, and fails to address the dynamic needs of medical practice. Its 2004 origin suggests obsolescence, with potential unintended consequences like reduced access to essential services and stifled innovation in healthcare delivery.

Amends the Health Insurance (Diagnostic Imaging Services Table) to update the list of eligible diagnostic imaging services and their corresponding fees

The regulation created a rigid and centrally planned pricing mechanism, which can lead to inefficiencies and restrict innovation in the diagnostic imaging services market, ultimately increasing costs for consumers and reducing access to better options

Amends the Health Insurance (Pathology Services Table) to update Medicare coverage and reimbursement rates for pathology services.

Keeping this instrument perpetuates government control over healthcare markets, distorting incentives, imposing compliance costs, and stifling innovation in diagnostic services. The centralized table prevents price competition and patient choice, leading to inefficiency and higher costs. Repealing it would allow a free market to deliver better outcomes.

This instrument amends the General Medical Services Table (GMST), which defines the Medicare Benefits Schedule (MBS) - the schedule of medical services and associated Medicare rebates payable to practitioners. It modifies item descriptors, adds new medical service items, or adjusts benefit rates for specific procedures and consultations under Australia's universal health insurance scheme.

This regulation embodies price controls in healthcare that distort market signals, create artificial shortages in underfunded service areas, generate perverse billing incentives (upcoding, supplier-induced demand), and impose significant compliance burden on practitioners navigating thousands of complex MBS items. While practical transition challenges exist if deleted, the underlying framework should be fundamentally reformed rather than maintained - Australians would benefit from a system that allows genuine price competition in healthcare rather than centralized price-setting that consistently overpays for some services while undercompensating others, ultimately harming both patients and practitioners through misallocated resources and restricted choice.

Amends the Diagnostic Imaging Services Table under the Health Insurance Act to determine which imaging services receive Medicare benefits and set their rebate amounts, effectively controlling prices and mandating coverage for specific procedures.

Price controls distort market signals, leading to under-provision of services, reduced quality, and slower adoption of new technologies. Mandated coverage limits consumer choice and stifles private insurance innovation. The unseen costs include longer wait times, misallocation of resources, and the crowding out of competitive market solutions that would otherwise expand access and improve efficiency.

Amendment to the Medicare Benefits Schedule (MBS) that modifies coverage rules, item descriptors, and benefit amounts for general medical services. This regulation is part of the ongoing adjustment of what procedures Medicare subsidizes and at what rates, affecting reimbursement levels for doctors and access patterns for patients.

This regulation perpetuates Medicare's price-control mechanism on medical services, which distorts healthcare markets by setting maximum prices below equilibrium, reducing provider supply and creating artificial shortages. The MBS system itself creates moral hazard through third-party payment, inflates healthcare costs, and removes price signals that would otherwise guide efficient resource allocation. Government determination of 'appropriate' medical service values is inherently paternalistic and substitutes bureaucratic judgment for individual choice. Rather than addressing healthcare access through subsidy, a freer market approach would allow competition, price transparency, and voluntary insurance to serve consumers more efficiently.

Amendment to the General Medical Services Table regulating Medicare Benefits Schedule item descriptors, fees, and conditions for medical services. Establishes the regulated prices and conditions for government-subsidized medical procedures, affecting what doctors can charge and patients can claim for consultations, procedures, and treatments under Australia's Medicare system.

This instrument maintains price controls on medical services through the Medicare Benefits Schedule, distorting healthcare markets by fixing fees rather than allowing competitive pricing. Such regulation restricts supply, creates bulk-billing distortions, discourages innovation in service delivery, and layers compliance costs on medical practitioners. Australians would be better served by a system where medical pricing emerges from voluntary contracts and genuine competition, not bureaucratic fee-setting.

Amended the Health Insurance (General Medical Services Table) Regulations to modify Medicare Benefits Schedule (MBS) item descriptors, fees, and eligibility criteria for various medical services. These regulations prescribe which medical services are eligible for Medicare rebates and the maximum benefit amounts payable, affecting what doctors and patients can claim for consultations, procedures, and specialist services across Australia's public health insurance system.

Government price-fixing of medical fees through the MBS creates artificial supply-demand imbalances, distorting healthcare markets. The regulation assumes bureaucrats can set appropriate fees across all medical specialties and regions — an economic calculation problem Mises identified. Unintended consequences include bulk-billing deserts in rural areas, specialist shortages, prolonged wait times, and barriers to innovation in medical technology. Friedman argued healthcare markets could function with consumer sovereignty and targeted safety nets rather than comprehensive price controls. A system of targeted vouchers or tax incentives for low-income Australians would achieve access goals without centralized fee-setting that harms all Australians through reduced supply and longer wait times.

Amendment to Customs (Prohibited Imports) Regulations, modifying the list or conditions of prohibited imports. Specific provisions not provided.

Import prohibitions create unnecessary barriers to trade, raising costs for consumers and businesses while distorting market signals. This amendment likely perpetuates or expands those burdens, adding compliance overhead without clear evidence of overriding benefit. Removing it would reduce red tape and enhance Australia's competitiveness.

Amendment to the Health Insurance Act 1973 regulations governing diagnostic imaging services (MRI, CT, ultrasound, X-ray, etc.) under Medicare. Sets the Medicare Benefits Schedule (MBS) items, rebate amounts, and quality standards for diagnostic imaging providers billing Medicare.

This instrument is part of the regulatory apparatus that controls diagnostic imaging prices through Medicare rebates, creating artificial price distortions that contribute to long public waiting lists and provider shortages. The MBS system rations diagnostic imaging based on government-set prices rather than market demand, leading to waiting times that harm patients. Compliance costs for providers participating in Medicare are substantial, reducing competition and innovation. Price controls on diagnostic imaging services, as with all price controls, distort supply and demand, resulting in shortages that are only masked by the government's role as the primary payer. The regulatory burden falls disproportionately on smaller imaging practices, reducing market competition. Australians would be better served by a system where diagnostic imaging pricing reflects market conditions and patients can access services based on demand rather than bureaucratic allocation.

Amends the Medicare Benefits Schedule, setting fees and coverage for medical services under Australia's universal health insurance scheme.

Price controls and central planning in healthcare create massive compliance costs, distort incentives, reduce innovation and quality, and impose deadweight losses. The bureaucratic overhead of maintaining this schedule far exceeds any benefits.

Regulates which diagnostic imaging services are covered by health insurance, establishing a table of approved services

Creates unnecessary regulatory burden that distorts market incentives, increases compliance costs for providers, and may restrict access to necessary medical services while offering limited public benefit

Amends fishing levies to impose taxes on fishing activities, likely aimed at generating revenue for marine conservation or fisheries management.

Fishing levies impose unnecessary costs on an industry critical to Australia's resources sector. Regulatory taxes distort incentives, reduce competitiveness, and burden a sector already strained by environmental compliance and approval timelines. The intended 'public good' of marine conservation is better achieved through market-based solutions rather than regulatory taxation.

Amends the pathology services table to specify covered services under health insurance, enacted in 2005.

Obsolescent regulation imposing unnecessary bureaucratic constraints on healthcare coverage with no demonstrable benefit, contributing to systemic inefficiencies in healthcare funding and access

Amends the Health Insurance (Pathology Services Table) Regulations by modifying the schedule of Medicare rebates for pathology laboratory services, including adjustments to item numbers, descriptor definitions, and fee structures for diagnostic pathology tests performed by approved pathology laboratories.

This regulation perpetuates Medicare's price control regime over pathology services, distorting market signals and creating artificial supply constraints. By maintaining government-set rebates for pathology, it suppresses competition, discourages innovation, and causes the chronic underinvestment in pathology infrastructure seen in Australia. Pathology is a sector where market competition would naturally drive down costs and improve quality - the current system instead creates barriers to entry and allocates resources based on bureaucratic determination rather than consumer demand, harming Australian patients through reduced access and longer turnaround times.